First patient treated with Leqembi® (lecanemab) in the Nordics
BioAge Labs, Inc. (BIOA)
Last bioage labs, inc. earnings: 8/3 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
investor.bio-amber.com
Company Research
Source: PR Newswire
STOCKHOLM, Oct. 14, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that Leqembi has now been made available at a private clinic in Finland and that the first patient has started treatment. BioArctic copromotes Leqembi with its partner Eisai in the Nordic countries, and this marks an important strategic step for BioArctic on the company's journey towards building Sweden's next major pharmaceutical company."I am very happy that we are now starting to help people diagnosed with early Alzheimer's disease also in the Nordic countries. There is a significant unmet need for new treatment options that slow the progression of Alzheimer's disease from its early stage, and to reduce the overall burden on people affected by Alzheimer's disease, as well as care partners and society," said Gunilla Osswald, CEO at BioArctic. "It is great to see that this innovation, based on Professor Lars Lannfelts research at Uppsala University here in Sweden, is finally, after
Show less
Read more
Impact Snapshot
Event Time:
BIOA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIOA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIOA alerts
High impacting BioAge Labs, Inc. news events
Weekly update
A roundup of the hottest topics
BIOA
News
- BioAge Labs (NASDAQ:BIOA) was upgraded by analysts at Morgan Stanley from an "underweight" rating to an "equal weight" rating. They now have a $12.00 price target on the stock.MarketBeat
- BioAge Labs BGE-102 Phase 1 Trial Shows Potential in Targeting Inflammation in Central Nervous System, Peripheral Tissues [Yahoo! Finance]Yahoo! Finance
- BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 InhibitorGlobeNewswire
- New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatmentPR Newswire
- New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatmentPR Newswire
BIOA
Earnings
- 11/6/25 - Beat
BIOA
Sec Filings
- 12/4/25 - Form 144
- 12/4/25 - Form 8-K
- 11/6/25 - Form 10-Q
- BIOA's page on the SEC website